These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38963035)

  • 21. A Method for Liposome Co-encapsulation of Phenethyl Isothiocyanate and Cisplatin and Determining Its Toxicity Against Lung and Lung Cancer Cells.
    Sun M; Di Pasqua AJ
    Methods Mol Biol; 2021; 2279():241-253. PubMed ID: 33683699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).
    Wang Y; Wu Y; Xie S
    Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.
    Ji XM; Ouyang B; Liu H; Liu GW; Wu ZC; Yu HY; Wang CY; Wang ZX; Wang WP
    Chin J Integr Med; 2011 Dec; 17(12):908-16. PubMed ID: 22139542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
    Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
    Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment.
    Mao K; Zhang W; Yu L; Yu Y; Liu H; Zhang X
    Drug Des Devel Ther; 2021; 15():3475-3486. PubMed ID: 34413632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Delivery of Cisplatin-Derived Nanoprecursors via a Biomimetic Yeast Microcapsule for Tumor Therapy by the Oral Route.
    Zhou X; Ling K; Liu M; Zhang X; Ding J; Dong Y; Liang Z; Li J; Zhang J
    Theranostics; 2019; 9(22):6568-6586. PubMed ID: 31588236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer.
    Sun M; Shi Y; Dang UJ; Di Pasqua AJ
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30813352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.
    Liu S; Chen D; Zhu X; Wang X; Li X; Du Y; Zhang P; Tian J; Song Y
    Drug Deliv Transl Res; 2024 Nov; 14(11):3147-3162. PubMed ID: 38381317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antitumor activity of PNA modified vinblastine cationic liposomes on Lewis lung tumor cells: In vitro and in vivo evaluation.
    Li XT; He ML; Zhou ZY; Jiang Y; Cheng L
    Int J Pharm; 2015 Jun; 487(1-2):223-33. PubMed ID: 25895716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
    Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
    J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice.
    Dou YN; Zheng J; Foltz WD; Weersink R; Chaudary N; Jaffray DA; Allen C
    J Control Release; 2014 Mar; 178():69-78. PubMed ID: 24440663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
    Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
    Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
    Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
    Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation and evaluation of a novel liposomal formulation of cisplatin.
    Zhou X; Wang J; Wu J; Yang X; Yung BC; Lee LJ; Lee RJ
    Eur J Pharm Sci; 2015 Jan; 66():90-5. PubMed ID: 25446511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X
    Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.